PSY-PGx develops a genotyping approach for individualized pharmacotherapy to improve treatment outcomes in patients with anxiety, depression and psychotic disorders.
Today, medication selection in psychiatry relies on a trial-and-error approach that combines physicians’ experience with clinical indicators. Pharmacogenetic (PGx) testing can help reduce uncertainty in this process by determining the person-specific genetic factors that predict clinical response and side effects associated with genetic variants that impact drug-metabolizing enzymes, drug transporters or drug targets, where differences in metabolism are by far most important.
PSY-PGx is the first non-commercial, large-scale, international initiative with the overarching aim to provide best quality of care, to reduce personal suffering as well as the societal and financial burden of psychiatric disorders. To achieve this, an early stage clinical trial in psychiatric patients will be performed using individual patient characteristics, including pharmacogenes to personalize medication prescription.